As these clinical studies have highlighted the concept of immune remodeling via the CCR5 axis, our pre-clinical data point to a direct anticancer effect of maraviroc in breast, pancreatic and CRC cells (Huang et al. 2020; Pervaiz et al. 2015, 2019). This evidence concerns the gene CCR5 and colorectal carcinoma.